Diseases & Longevity · File 19

Central obesity. BMI doesn't capture real risk — visceral fat does.

Central obesity — excess abdominal visceral fat — is a cardiovascular and metabolic predictor independent of BMI. Patients with "normal" BMI but increased waist circumference (TOFI — thin outside, fat inside) have significant cardiometabolic risk. Visceral fat functions as an aggressor endocrine organ — producing inflammatory cytokines, altered adipokines, and lipids that sustain the cluster.

Why waist circumference beats BMI

The BMI treats every patient with the same weight as equally risky — but a kilogram of visceral abdominal fat is not equivalent to a kilogram of muscle or peripheral subcutaneous fat. Visceral fat is metabolically active: drains directly to the portal system, saturates the liver with free fatty acids, produces pro-inflammatory cytokines (IL-6, TNF-α), and altered adipokines (high leptin, low adiponectin). It is an aggressor endocrine organ.

Waist circumference (>102 cm men, >88 cm women per ATP-III) is a predictor independent of BMI for T2D, CV events, and mortality (Despres 2012 Circulation). That is why longevity medicine measures body composition with DEXA when applicable, waist circumference systematically, and waist-hip ratio — not just BMI. Without that reading, the risk in borderline-BMI patients remains invisible.

A "normal" BMI with increased waist circumference is the TOFI scenario — the most underdiagnosed epidemiological trap of the cluster.
Adults with obesity · WHO 2022

The global weight, in numbers

Obesity continues to grow globally, and central obesity — more predictive — even faster in middle-income countries.

  • Global burden

    ~13% adultos · 2022

    Approximately 13% of adults globally have obesity (BMI ≥30). The figure is significantly higher in US (>42%), Middle East, Latin America, and grows fast in Asia.
    — WHO Obesity Fact Sheet 2022; NCD-RisC 2017

  • Waist vs BMI

    Predictor independiente

    Waist circumference predicts cardiovascular events and mortality independently of BMI. Patients with normal BMI but elevated waist (TOFI) have significant cardiometabolic risk.
    — Despres, Circulation 2012

  • GLP-1 change the paradigm

    Semaglutida 2.4 mg · −15% peso

    STEP 1 (Wilding 2021 NEJM): weekly semaglutide 2.4 mg reduces weight ~15% at 68 weeks. SURMOUNT-1 (Jastreboff 2022): tirzepatide reduces ~20%. Also reduce CV events and improve MASLD, BP, lipid profile.
    — Wilding NEJM 2021; Jastreboff NEJM 2022

  • Bariatric surgery

    Mortalidad −30% a 10a

    Longitudinal studies (Swedish Obese Subjects, Adams 2017) show significant reduction of total and CV mortality after bariatric surgery vs non-surgical control. Multidisciplinary decision with bariatric surgeon when indicated.
    — Adams et al., NEJM 2017

Chap. 03 · Amplified cardiometabolic

Impact on cardiometabolic cluster and comorbidity

Central obesity is not aesthetic — it is the amplifier of the cardiometabolic cluster and of multiple systemic comorbidities.

  • Type 2 diabetes

    Riesgo ×4-7

    Central obesity is the strongest T2D predictor — visceral tissue insulin resistance is the central mechanism. 5-10% weight reduction significantly decreases incidence.
    — DPP Knowler 2002; ADA 2024

  • Associated cancers

    13 tipos · IARC

    IARC has identified 13 cancers associated with obesity — including postmenopausal breast, colorectal, endometrium, kidney, liver, esophagus, pancreas, and others. Mechanism is chronic inflammation + adipokines + insulin/IGF-1.
    — Lauby-Secretan, NEJM 2016

  • Sleep apnea (OSA)

    Comorbilidad alta

    Central obesity is the factor most associated with OSA. OSA amplifies the cluster — AF, resistant HTN, depression, cognitive decline. Polysomnography is frequent indication in central obesity with suggestive symptoms.
    — Lévy et al., Nat Rev Dis Primers 2015

  • Quality of life and mobility

    PCS↓ + estigma

    Central obesity significantly reduces SF-36 PCS, functional capacity, and worsens osteoarthritis, low back pain, and incontinence. Social stigma adds psychosocial burden frequently unaddressed in consultation.
    — Hu et al., BMC Public Health 2024

What we don't offer — and what we do

Wellness Care is not a weight loss clinic. We do not prescribe GLP-1 (semaglutide, tirzepatide) in monotherapy without integrated clinical context, we don't perform bariatric surgery, and don't manage surgical complications. Final pharmacological decision belongs to the endocrinologist / bariatric surgeon. What we do is what the conventional system rarely integrates: complete cardiometabolic evaluation, body composition with DEXA, and cluster approach.

We evaluate patients with cardiometabolic cluster (HTN + dyslipidemia + T2D + central obesity), TOFI (normal BMI with increased waist), family history of diabetes or early CV events, MASLD, OSA, sarcopenia with coexisting obesity, or those under endocrinology follow-up wanting to optimize the longevity view. Intervention integrates structured lifestyle, advanced biomarker profile, and endocrinology coordination.

Central obesity is not a weight problem — it is an aggressor endocrine organ problem. The longevity view reads the cluster, not the scale.
How we measure it

How central obesity is evaluated
at Wellness Care

Quantitative body composition + complete cardiometabolic profile + inflammaging + comorbidities. In endocrinology coordination when indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the modern obesity conversation — Despres, IARC cancers, STEP 1 / SURMOUNT-1, DPP prevention.

«La grasa abdominal visceral es predictor independiente del IMC para diabetes, eventos cardiovasculares y mortalidad — funciona como un órgano endocrino agresor.»
Circulation · 2012
Despres, Circulation 2012
Grasa visceral como predictor
«La IARC identifica 13 cánceres con evidencia suficiente de asociación con obesidad — incluyendo mama postmenopáusico, colorrectal, endometrio, riñón, hígado y otros.»
NEJM · 2016
Lauby-Secretan et al., NEJM 2016
IARC · obesidad y cáncer
«Semaglutida 2.4 mg semanal reduce el peso corporal aproximadamente un 15% a 68 semanas en pacientes con obesidad.»
NEJM · 2021
Wilding et al., NEJM 2021
STEP 1 · semaglutida

Frequently asked questions about central obesity

The most recurrent questions about central obesity, GLP-1s, bariatric surgery, and why longevity medicine treats it as part of the cardiometabolic cluster.

01

Is BMI really useful today?

BMI is useful as population screening but limited at individual level.

Does not distinguish between:

· Muscle mass
· Subcutaneous fat
· Visceral fat

Athletic patients can have high BMI without risk; TOFI patients have normal BMI with significant cardiometabolic risk.

Longevity medicine complements BMI with:

· Waist circumference
· Waist-hip ratio
· Body composition (DEXA or BIA)
· Biomarkers

02

Are GLP-1s safe long-term?

To date (2026), 5+ year safety data of GLP-1s are favorable.

Most frequent adverse effects:

· Gastrointestinal — nausea, constipation (generally mild and manageable)

Safety signals to monitor:

· Gastroparesis
· Pancreatitis
· Thyroid tumors in animal models (not confirmed in humans)

Muscle mass loss during rapid weight loss is real — requires strength training and adequate protein as accompaniment.

03

Does bariatric surgery really change the trajectory?

Yes — significantly, in selected patients.

Longitudinal studies (Adams 2017 NEJM, Swedish Obese Subjects) show:

· ~30% total mortality reduction at 10 years after gastric bypass
· Improvement of T2D, HTN, dyslipidemia, MASLD

Indication is multidisciplinary decision with bariatric surgeon, considering:

· Clinical profile
· Comorbidities
· Preferences
· Surgical risk

04

Which lifestyle interventions are most effective?

Best-evidence interventions:

· Mediterranean or DASH diet (sustained moderate caloric deficit)
· Progressive strength training + cardio (preserve muscle mass during weight loss)
· Regulated sleep — chronic deprivation deregulates leptin/ghrelin
· Stress management — chronic cortisol favors visceral fat
· Avoid alcohol
· Simple sugar / ultra-processed restriction

Structured behavioral support significantly improves adherence.

05

When should I consult?

A structured assessment is worthwhile if you have:

· BMI ≥25 with cardiometabolic cluster
· Normal BMI with increased waist (TOFI)
· Family history of T2D / early MI
· Detected MASLD
· Suspected OSA
· Sarcopenia with coexisting obesity
· Difficulty sustaining weight loss
· Want to understand your cardiometabolic trajectory before clinical disease

The assessment complements endocrinology — does not replace it.

The aggressor endocrine organ

Central obesity is not a weight problem — it is an aggressor endocrine organ problem. The longevity view reads the cluster, not the scale.

Measure body composition with DEXA, waist circumference, advanced cardiometabolic profile, inflammaging, and coordinate with endocrinology when pharmacological or surgical indication exists — that's what changes real trajectory.

Increased waist circumference or cardiometabolic cluster?

Book a comprehensive cardiometabolic assessment

We evaluate body composition (DEXA when applicable), metabolic profile (HbA1c, insulin, HOMA index), advanced lipid profile (ApoB, Lp(a)), hepatic profile (FIB-4), inflammaging, hormonal profile, and the 14 Lancet Commission factors. Does not replace endocrinology — it complements.

Book metabolic assessment